Physician profile
Francesca Polverino
NPI 1760140420
$75,266.11
in general payments reported to CMS, 2019-2025
10 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $300 · 2023: $3,892 · 2024: $44K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Travel and Lodging: $11K · Food and Beverage: $2,700 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,651.00 |
| Travel and Lodging | $11,016.73 |
| Food and Beverage | $2,700.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,598.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $29,853.88 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $19,403.18 | 2024-2025 | Fasenra, Breztri, Tezspire |
| Amgen INC. | $9,228.18 | 2024 | |
| Astrazeneca Uk Limited | $8,271.54 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $4,332.00 | 2024 | Dupixent |
| Genentech, INC. | $3,847.42 | 2023-2025 | |
| Grifols Shared Services North America, INC. | $120.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $95.00 | 2024-2025 | Dupixent |
| Polarean, INC. | $87.74 | 2025 | Xenoview |
| Verona Pharma, INC. | $27.17 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Polverino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.